Key Scientific Achievements in Gastroenterology in 2024: Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences
O. M. Drapkina,
I. V. Maev,
D. S. Bordin,
I. G. Bakulin,
E. V. Garbuzova,
A. I. Ershova,
M. A. Livzan https://doi.org/10.15829/1728-8800-2025-4386
EDN: ZJSXRV
Abstract
19.12.2024 состоялось очередное заседание Совета по терапевтическим наукам Секции клинической медицины РАН, посвященное ключевым научным достижениям гастроэнтерологии в 2024 г. В ходе заседания обсуждались актуальные вопросы гастроэнтерологической практики, включая проблемы профилактики рака желудка у пациентов с хроническим гастритом, а также приоритетные направления в диагностике и лечении патологии печени и различных заболеваний кишечника.
About the Authors
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine; Russian University of Medicine
Russian Federation
Russian Federation
Moscow
I. V. Maev
Russian University of Medicine
Russian Federation
Russian Federation
Moscow
D. S. Bordin
Russian University of Medicine; Tver State Medical University; Loginov Moscow Clinical Scientific Center
Russian Federation
Russian Federation
Moscow; Tver
I. G. Bakulin
I.I. Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
St. Petersburg
E. V. Garbuzova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. I. Ershova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
Omsk
References
1. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. doi:10.1136/gutjnl-2022-327745.
2. Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99. (In Russ.) doi:10.22416/1382-4376-2021-31-4-70-99.
3. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024; 73(3):407-41. doi:10.1136/gutjnl-2023-331164.
4. Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19. doi:10.1038/s41572-023-00431-8.
5. Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. doi:10.1111/hel.12924.
6. Bakulina NV, Tikhonov SV, Savilova IV et al. Dynamics of the prevalence of Helicobacter pylori infection from 2015 to 2023. I. I. Mechnikov Herald of North-Western State Medical University. 2023;15(3):41-51. (In Russ.) doi:10.17816/mechnikov623259.
7. Bordin DS, Kuznetsova ES, Stauver EE. Prevalence of Helicobacter pylori infection in various diseases and in cohort studies conducted in the Russian Federation from 1990 to 2023: a systematic review. Effective Pharmacotherapy. 2024;20(30):24-33. (In Russ.) doi:10.33978/2307-3586-2024-20-30-24-33.
8. Lazebnik LB, Vasiliev YuV, Shcherbakov PL, et al. Helicobacter pylori: prevalence, diagnosis, treatment. Experimental and Clinical Gastroenterology. 2010;2:3-7. (In Russ.)
9. Plummer M, Franceschi S, Vignat J. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136: 487-90. doi:10.1002/ijc.28999.
10. Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Moscow: P. A. Herzen Moscow Oncology Research Institute — branch of the Federal State Budgetary Institution "NMITs of Radiology" of the Ministry of Health of the Russian Federation, 2024. p. 276. (In Russ.) ISBN 978-5-85502-298-8.
11. Chen YC, Malfertheiner P, Yu HT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024;166(4):605-19. doi:10.1053/j.gastro.2023.12.022.
12. Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022; 47:101404. doi:10.1016/j.eclinm.2022.101404.
13. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435-45. doi:10.1007/s10120-018-0876-0.
14. Choi IJ, Kim CG, Lee JY, et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med. 2020;382(5): 427-36. doi:10.1056/NEJMoa1909666.
15. Huang RJ, Epplein M, Hamashima C, et al. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol. 2022;20(10):2218-28.e2. doi:10.1016/j.cgh.2021.09.039.
16. Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243-50. doi:10.1136/gutjnl-2020-322200.
17. Kowada AA. Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening. Dig Dis Sci. 2023;68(5):1735-46. doi:10.1007/s10620-022-07795-z.
18. Bujanda L, Nyssen OP, Ramos J, et al. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2024;119(4):646-54. doi:10.14309/ajg.0000000000002600.
19. Jonaitis P, Nyssen OP, Saracino IM, et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023;13(1):17235. doi:10.1038/s41598-023-43287-4.
20. Pabon-Carrasco M, Keco-Huerga A, Castro-Fernández M, et al. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(1):122-38. doi:10.1002/ueg2.12476.
21. Nishizawa T, Nishizawa Y, Yahagi N, et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4. doi:10.1111/jgh.12769.
22. Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. doi:10.3390/jcm8091498.
23. Bordin DS, Abdulkhakov SR, Andreev DN et al. Effectiveness of rebamipide-containing first-line empirical eradication therapy in Russia: results from the european registry on Helicobacter pylori management (HP-EUREG). European Helicobacter and Microbiota Study Group (EHMSG) Abstracts Microb Health Dis. 2024;6:75-6. doi:10.26355/mhd_20249_1023.
24. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-88. doi:10.1055/a-0859-1883.
25. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017;152(6):1319-28.e7. doi:10.1053/j.gastro.2017.01.029.
26. Alexandrescu L, Suceveanu AP, Stanigut AM, et al. Intestinal Insights: The Gut Microbiome's Role in Atherosclerotic Disease: A Narrative Review. Microorganisms. 2024;12(11):2341. doi:10.3390/microorganisms12112341.
27. Luqman A, Hassan A, Ullah M, et al. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder. Front Immunol. 2024;15:1321395. doi:10.3389/fimmu.2024.1321395.
28. Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients. 2020;12:1082. doi:10.3390/nu12041082.
29. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, et al. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4(4):659-72. doi:10.1007/s12072-010-9219-x.
30. Malan-Müller S, Martín-Hernández D, Caso JR, et al. Metagenomic symphony of the intestinal ecosystem: How the composition affects the mind. Brain Behav Immun. 2025;123:510-23. doi:10.1016/j.bbi.2024.09.033.
31. Shkoporov AN, Hill C. Bacteriophages of the Human Gut: The "Known Unknown" of the Microbiome. Cell Host Microbe. 2019;25(2):195-209. doi:10.1016/j.chom.2019.01.017.
32. Duerkop BA, Hooper LV. Resident viruses and their interactions with the immune system. Nat Immunol. 2013;14(7):654-9. doi:10.1038/ni.2614.
33. Liu T, Huang Z. Evidence-based analysis of neurotransmitter modulation by gut microbiota: 8th International Conference on Health Information Science, HIS 2019. Health Information Science. 2019;238-49. doi:10.1007/978-3-030-32962-4_22.
34. Zhao Y, Yang H, Wu P, et al. Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders. Virulence. 2024;15(1):2375555. doi:10.1080/21505594.2024.2375555.
35. Alam A, Leoni G, Quiros M, et al. The microenvironment of injured murine gut elicits a local prorestitutive microbiota. Nat Microbiol. 2016;1:15021. doi:10.1038/nmicrobiol.2015.21.
36. Zhang T, Li P, Wu X, et al. Alterations of Akkermansia muciniphila in the inflammatory bowel disease patients with washed microbiota transplantation. Appl Microbiol Biotechnol. 2020;104(23):10203-15. doi:10.1007/s00253-020-10948-7.
37. Bian X, Wu W, Yang L, et al. Administration of Akkermansia muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. Front Microbiol. 2019;10:2259. doi:10.3389/fmicb.2019.02259.
38. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066-71. doi:10.1073/pnas.1219451110.
39. Cani PD, de Vos WM. Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765. doi:10.3389/fmicb.2017.01765.
40. Regnier M, Rastelli M, Morissette A, et al. Rhubarb Supplementation Prevents Diet-Induced Obesity and Diabetes in Association with Increased Akkermansia muciniphila in Mice. Nutrients. 2020;12(10):2932. doi:10.3390/nu12102932.
41. Noemi CN, Bob P, Bókkon I. Long-Term Implicit Epigenetic Stress Information in the Enteric Nervous System and its Contribution to Developing and Perpetuating IBS. Curr Neuropharmacol. 2024;22(13):2100-12. doi:10.2174/1570159X22666240507095700.
42. Sulkowska SEM. The impact of maternal gut microbiota during pregnancy on fetal gut-brain axis development and life-long health outcomes. Microorganisms. 2023;11(9):2199. doi:10.3390/microorganisms11092199.
43. Rusch JA, Layden BT, Dugas LR. Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. Front Endocrinol (Lausanne). 2023;14:1130689. doi:10.3389/fendo.2023.1130689.
44. Misiak B, Łoniewski I, Marlicz W, et al. The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota? Prog Neuropsychopharmacol Biol Psychiatry. 2020;102: 109951. doi:10.1016/j.pnpbp.2020.109951.
45. Turroni F, Rizzo SM, Ventura M, Bernasconi S. Cross-talk between the infant/maternal gut microbiota and the endocrine system: a promising topic of research. Microbiome Res Rep. 2022;1(2):14. doi:10.20517/mrr.2021.14.
46. Zuo T, Liu Q, Zhang F, et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91. doi:10.1186/s40168-021-01008-x.
47. Yu LC. Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms. Life Sci. 2024;358:123153. doi:10.1016/j.lfs.2024.123153.
48. Aggeletopoulou I, Triantos C. Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome. Int J Mol Sci. 2024;25(22):12395. doi:10.3390/ijms252212395.
49. Li C, Li J, Zhou Q, et al. Effects of Physical Exercise on the Microbiota in Irritable Bowel Syndrome. Nutrients. 2024;16(16): 2657. doi:10.3390/nu16162657.
50. Li J, Ghosh TS, Arendt E, et al. Cross-Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment. Adv Sci (Weinh). 2024;11(41):e2308313. doi:10.1002/advs.202308313.
51. Lembo AJ, Chey WD, Harris LA, et al. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis. Am J Gastroenterol. 2024;119(5):937-45. doi:10.14309/ajg.0000000000002685.
52. Gaus OV, Livzan MA. Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation. Terapevticheskii arkhiv. 2023;95(2):164-72. (In Russ.) doi:10.26442/00403660.2023.02.202111.
53. Gaus OV, Livzan MA. Phenotypes of irritable bowel syndrome and strategies for patient-oriented curation of patient. Lechaschi Vrach. 2023;7-8(26):36-44. (In Russ.) doi:10.51793/OS.2023.26.8.006.
54. Camargo Tavares L, Lopera-Maya EA, Bonfiglio F, et al. Rome III Criteria Capture Higher Irritable Bowel Syndrome SNP-Heritability and Highlight a Novel Genetic Link With Cardiovascular Traits. Cell Mol Gastroenterol Hepatol. 2024;18(2):101345. doi:10.1016/j.jcmgh.2024.04.002.
55. Kapizioni C, Desoki R, Lam D, et al. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. J Crohns Colitis. 2024;18(6):790-800. doi:10.1093/ecco-jcc/jjad203.
56. Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628-39. doi:10.1056/NEJMra1909094.
57. Bikbavova GR, Livzan MA, Lisyutenko NS, et al. Insulin resistance as a cardiovascular risk factor in patients with ulcerative colitis. Russian Journal of Evidence-Based Gastroenterology. 2024;13(3):42-9. (In Russ.) doi:10.17116/dokgastro20241303142.
58. Livzan MA, Bikbavova GR, Lisyutenko NS, et al. Cardiovascular Risk in Patients with Inflammatory Bowel Diseases-The Role of Endothelial Dysfunction. Diagnostics (Basel). 2024;14(16):1722. doi:10.3390/diagnostics14161722.
59. Marín-Jiménez I, Carpio D, Hernández V, et al. Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2024:502314. English, Spanish. doi:10.1016/j.gastrohep.2024.502314. Epub ahead of print.
60. Massironi S, Franchina M, Elvevi A, Barisani D. Beyond the gluten-free diet: Innovations in celiac disease therapeutics. World J Gastroenterol. 2024;30(38):4194-210. doi:10.3748/wjg.v30.i38.4194.
61. Haider MB, Al Sbihi A, Reddy SN, Green P. Prevalence of malignant neoplasms in celiac disease patients — a nationwide United States population-based study. World J Clin Oncol. 2024;15(8):1048-60. doi:10.5306/wjco.v15.i8.1048.
62. Shiha MG, Nandi N, Raju SA, et al. Accuracy of the No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: A Systematic Review and Meta-Analysis. Gastroenterology. 2024;166(4):620-30. doi:10.1053/j.gastro.2023.12.023.
63. Batsaikhan O, Chimed-Ochir O, Kubo T, et al. The burden of liver cancer in Mongolia from 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Front Oncol. 2024;14:1381173. doi:10.3389/fonc.2024.1381173.
64. Islami F, Dikshit R, Mallath MK, et al. Primary liver cancer deaths and related years of life lost attributable to hepatitis B and C viruses in India. Cancer Epidemiol. 2016;40:79-86. doi:10.1016/j.canep.2015.11.012.
65. Mohammadian M, Mahdavifar N, Mohammadian-Hafshejani A, et al. Liver cancer in the world: epidemiology, incidence, mortality and risk factors. WCRJ. 2018;5(2):e1082. doi:10.32113/wcrj_20186_1082.
66. Evstifeeva SE, Shalnova SA, Kutsenko VA, et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356. (In Russ.) doi:10.15829/1728-8800-2022-3356.
67. Maev IV, Andreev DN, Kucheryavyy Yu A. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum. 2023;25(5):313-9. (In Russ.) doi:10.26442/20751753.2023.5.202155.
68. Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: P. A. Herzen Moscow Oncology Research Institute — branch of the Federal State Budgetary Institution "NMITs of Radiology" of the Ministry of Health of the Russian Federation, 2020. p. 252. (In Russ.) ISBN: 978-5-85502-260-5.
69. Liu Z, Suo C, Mao X, et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. Cancer. 2020;126(10):2267-78. doi:10.1002/cncr.32789.
70. Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):71-102. (In Russ.) doi:10.22416/1382-4376-2016-4-71-102.
71. Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2022;76(1):195-201. doi:10.1016/j.jhep.2021.08.028.
72. Raikhelson KL, Maevskaya MV, Zharkova MS, et al. Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35-44. (In Russ.) doi:10.22416/1382-4376-2024-961.
73. Krolevets TS, Livzan VA. Non-alcoholic fatty liver disease: digest 2021. Russian Journal of Evidence-based Gastroenterology. 2021;10(2):27-35. (In Russ.). doi:10.17116/dokgastro20211002127.
74. Ishchenko AY, Galushko MY, Bakulin IG. The interrelation of cardiometabolic risk factors and metabolic dysfunction-associated steatotic liver disease subtypes. Meditsinskiy sovet. 2024;(15):146-57. (In Russ.) doi:10.21518/ms2024-447.
75. Liu Z, Lin C, Suo C, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022;127:154955. doi:10.1016/j.metabol.2021.154955.
76. Onishchenko NA, Gonikova ZZ, Nikolskaya AO, et al. Programmed cell death and liver diseases. Russian Journal of Transplantology and Artificial Organs. 2022;24(1):72-88. (In Russ.) doi:10.15825/1995-1191-2022-1-72-88.
77. An L, Wirth U, Koch D, et al. Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD. Metabolites. 2023;13(1):101. doi:10.3390/metabo13010101.
78. Gao Y, Zhang W, Zeng LQ, et al. Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy. Redox Biol. 2020;36:101635. doi:10.1016/j.redox.2020.101635.
79. Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14(5):259-69. doi:10.1038/nrendo.2018.10.
80. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24(4):255-72. doi:10.1038/s41580-022-00547-x.
81. Al-Bari MAA, Xu P. Molecular regulation of autophagy machinery by mTOR-dependent and -independent pathways. Ann N Y Acad Sci. 2020;1467(1):3-20. doi:10.1111/nyas.14305.
82. Jang M, Park R, Kim H, et al. AMPK contributes to autophagosome maturation and lysosomal fusion. Sci Rep. 2018;8(1):12637. doi:10.1038/s41598-018-30977-7.
Supplementary files
Review
For citations:
Drapkina O.M., Maev I.V., Bordin D.S., Bakulin I.G., Garbuzova E.V., Ershova A.I., Livzan M.A. Key Scientific Achievements in Gastroenterology in 2024: Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences. Cardiovascular Therapy and Prevention. 2025;24(4):4386. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4386. EDN: ZJSXRV
Views:
44
Email this article 
